Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer

Ohashi, Kadoaki; Kiura, Katsuyuki; Takigawa, Nagio; Umemura, Shigeki; Kondo, Naruhito; Takemoto, M.; Onoda, K; Aoe, Motoi; Tabata, Masahiro; Tanimoto, M.

doi:10.1097/jto.0b013e31811f3abb

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of tumor proliferation is an effective response to cytotoxic drug therapy. However, inflammatory necrosis-induced pseudoincreases in tumor volume and non-expression of specific serum tumor markers in some cancer patients have biased the evaluation of therapeutic efficacy after anticancer therapies ( Ohashi et al, 2007 ; Ichihara et al, 2008 ). Identification of a serum-specific tumor marker that can dynamically and truly reflect the degree of cell cycle inhibition in tumor cells is urgently needed.…”

Section: Discussionmentioning

confidence: 99%

QSOX2 Is an E2F1 Target Gene and a Novel Serum Biomarker for Monitoring Tumor Growth and Predicting Survival in Advanced NSCLC

Liu

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

BackgroundQuiescin Q6 sulfhydryl oxidase 2 (QSOX2), an enzyme that can be directly secreted into the extracellular space, is known to be associated with oxidative protein folding. However, whether QSOX2 is abnormally expressed in non-small cell lung cancer (NSCLC) and its role in tumor growth remains unclear.MethodsReal-time quantitative PCR (qPCR), immunohistochemistry (IHC), bioinformatics analyses were applied to analyze the expression pattern and prognostic significance of QSOX2 in NSCLC. Xenografts model, enzyme-linked immunosorbent assays (ELISA), western blot analysis (WB), and IHC were preformed to examine in vivo tumor suppression and intracellular and extracellular expression of QSOX2. Flow cytometry, WB and qPCR analyses were used to elucidate the role of QSOX2 in cell cycle regulation. Chromatin immunoprecipitation assay (ChIP) assay and Dual-Luciferase reporter assay were employed to investigate transcriptional regulation of QSOX2 by E2F Transcription Factor 1 (E2F1).ResultsQuiescin sulfhydryl oxidase 2 was significantly overexpressed in NSCLC and associated with poor survival in advanced-stage patients. The intracellular and extracellular expression of QSOX2 by tumor cells markedly decreased after anti-cancer therapy in vitro, in vivo and in the clinic. Moreover, QSOX2 silencing in NSCLC cell lines resulted in inhibition of cancer cell proliferation, induction of apoptosis, and decreased expression of cell division-related genes (CENPF and NUSAP1) and Wnt pathway activators (PRRX2 and Nuc-β-catenin). Mechanistically, QSOX2 was expressed periodically during cell cycle and directly regulated by E2F1.ConclusionsOur findings demonstrate that QSOX2 is directly regulated by E2F1 in the cell cycle, which is essential for the proliferation of NSCLC cells. Furthermore, QSOX2 is a prognostic indicator for NSCLC and may be developed into a biomarker for monitoring tumor burden and therapeutic progress.

show abstract

Section: Discussionmentioning

confidence: 99%

QSOX2 Is an E2F1 Target Gene and a Novel Serum Biomarker for Monitoring Tumor Growth and Predicting Survival in Advanced NSCLC

Liu

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

Pseudoprogression of Lung Cancer after Concomitant Chemoradiotherapy

Ichihara

Kiura²,

Takigawa³

et al. 2008

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

We observed re-enlargement of a squamous cell carcinoma without recurrence. The tumour regressed markedly after concomitant chemoradiotherapy, but within 1 month, we supposed that the tumour had enlarged again and resection was performed. The resected tissue showed evidence of haemorrhage and several lymphocytes and macrophages, but no malignant cells were detected. We herein report a rare case of lung cancer showing a pathological complete response despite re-enlargement of tumour lesion.

show abstract

Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer

Cited by 2 publications

References 4 publications

QSOX2 Is an E2F1 Target Gene and a Novel Serum Biomarker for Monitoring Tumor Growth and Predicting Survival in Advanced NSCLC

QSOX2 Is an E2F1 Target Gene and a Novel Serum Biomarker for Monitoring Tumor Growth and Predicting Survival in Advanced NSCLC

Pseudoprogression of Lung Cancer after Concomitant Chemoradiotherapy

Contact Info

Product

Resources

About